Energy metabolism of human LoVo colon carcinoma cells: Correlation to drug resistance and influence of lonidamine

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1590-1597

  Fanciulli, Maurizio ^a   Bruno, Tiziana ^a   Giovannelli, Aldo ^a,b   Gentile, Francesco P ^a   Di Padova, Monica ^a   Rubiu, Oriana ^a   Floridi, Aristide ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CELL SURFACE PROTEIN; DOXORUBICIN; LONIDAMINE;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG UPTAKE; ENERGY METABOLISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CARBON DIOXIDE; CELL DIVISION; CITRATE (SI)-SYNTHASE; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; GLUCOSE; HEXOKINASE; HUMANS; INDAZOLES; INHIBITORY CONCENTRATION 50; ISOCITRATE DEHYDROGENASE; KINETICS; LACTIC ACID; TUMOR CELLS, CULTURED;

EID: 0034089167     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Simon, S. M., and Schindler, M. Cell biologic mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA, 91: 3497-3504, 1994.
2. Kartner, N. Riordan, J. R., and Ling, V. Cell surface P-glycoprotein associated with multidrug resistance n mammalian cell lines. Science (Washington DC), 221: 1285-1287,1983.
3. Center, M. S. Mechanisms regulating cell resistance to adriamycin. Biochem. Pharmacol., 13: 145-147 1985.
4. Scheper, R. J., Broxterman, H. J., Scheffer, G. M., Meijer, C. J. L. M., and Pinedo, H. M. Drug transporter protein in clinical multidrug resistance. Clin. Chim. Acta, 206: 25-27, 1992.
5. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transportes. Annu. Rev. Biochem., 62: 385-427, 1993.
6. Warburg, O. On the origin of the cancer cell. Science (Washington DC), 123: 309-314, 1956.
7. Aisemberg, A. C. The Glycolysis and Respiration of Tumor. New York: Academic Press, 1961.
8. Burk, D., Woods, M., and Hunter, J. On the significance of glucolysis for cancer growth with special reference to Morris hepatomas. J. Natl. Cancer Inst., 138: 839-863, 1967.
9. Goldeberg, E. B., and Colowick, S. P. The role of glycolysis in the growth of tumor cells. J. Biol. Chem., 240: 2876-2890, 1965.
10. Wu, R. Control mechanisms of glycolysis in Ehrlich ascites tumor cells. J. Biol. Chem., 240: 2827-2832, 1965.
11. Nakashima, R. A., Paggi, M. G., and Pedersen, P. L. Contributions of glycolysis and oxidative phosphorylation to adenosine-5′-triphosphate in AS-30D hepatoma cells. Cancer Res., 44: 5702-5706,1984.
12. Pedersen, P. L. Tumor mitochondria and bioenergetics of cancer cells. Prog. Exp. Tumor Res., 22: 190-274, 1978.
13. Lyon, R. C., Cohen, J. S., Faustino, P. J., Megnin, F., and Myers, C. E. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res., 48: 870-877, 1988.
14. Kaplan, O., Navon, G., Lyon, R. C., Faustino, P. J., Straka, E. J., and Cohen, J. S. Effect of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res, 50: 544-551, 1990.
15. 31P nuclear magnetic resonance and toxicity studies. Cancer Res., 50: 6936-6943, 1990.
16. Fanciulli, M., Valentini, A., Bruno, T., Citro, G., Zupi, G., and Floridi, A. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. Oncol. Res., 8: 111-120, 1996.
17. Fanciulli, M., Bruno, T., Castiglione, S., Del Carlo, C., Paggi, M. G., and Floridi, A. Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells. Oncol. Res., 5: 357-362, 1993.
18. Miccadei, S., Fanciulli, M., Bruno, T., Paggi, M. G., and Floridi, A. Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells. Oncol. Res., 8: 27-35, 1996.
19. Floridi, A., Paggi, M. G., Marcante, M. L., Silvestrini, B., Caputo, A., and De Martino, C. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J. Natl. Cancer Inst., 66: 497-499, 1981.
20. Floridi, A., Paggi, M. G., D'Atri, S., De Martino, C., Marcante, M. L., Silvestrini, B., Caputo, A. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res., 41: 4661-4666, 1981.
21. Floridi, A., and Lehninger, A. L. Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch. Biochem. Biophys., 226: 73-83, 1983.
22. Yang, L. Y., and Trujillo, J. M., Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods. Cancer Res., 50: 3218-3225, 1990.
23. Cenciarelli, C., Currier, S. J., Willingham, M. C., Thiebaut, F., Gemann, U. A., Rutheford, A. V., Gottesman, M. M., Barca, S., Tombesi, M., Morrone, S., Santoni, A., Marlani, M., Ramoni, C., Dupuis, M. L., and Cianfriglia, M. Characterisation by somatic cell genetics of a monoclonal antibody to MDR1 gene product (P-glycoprotein): determination of P-glycoprotein expression in multi-drug resistance KB and CEM cell variants. Int. J. Cancer, 47: 533-543, 1991.
24. Nuti, M., Zupi, G., D'Agnano, I., Turchi, V., Candiloro, A., and Frati, L. Antigenic expression changes occurring in adriamycin-resistant MCF7 mammary carcinoma cells. Anticancer Res., 11: 1225-1230, 1991.
25. Gentile, F. P. Chiatti, L., Mauro, F., Briganti, G., Floridi, A., and Benassi, M. Interaction of cytotoxic agents: a rule-based system for computer-assisted cell survival analysis. Anticancer Res., 12: 637-644, 1992.
26. Floridi, A., Gentile, F. P., Bruno, T., Delpino, A., Iacobini, C., Paggi, M. G., Castiglione, S., and Benassi, M. Thermal behavior of human glioma cells line and its response to combinations of hyperthermia and lonidamine. Oncol. Res., 5: 1-10, 1993.
27. Ara, G., and Teicher, B. A. Relationship of cellular metabolism parameters to cytotoxicity for AG-17, lonidamine and cyclocreatine in four human tumors cell lines. Int. J. Oncol., 8: 865-873, 1996.
28. Floridi, A., Gentile, F. P., Bruno, T., Castiglione, S., Zeuli, M., and Benassi, M. Growth inhibition by rhein and lonidamine of human glioma cells in vitro. Anticancer Res., 10: 1633-1636, 1990.
29. Cividalli, A., Gentile, F. P., Alonzi, A., Benassi, M., Mauro, F., and Floridi, A. In vivo control of tumor growth by lonidamine and radiation: influence of the timing and sequence of drug administration and irradiation treatment. Int. J. Oncol., 1: 561-565, 1992.
30. Teicher, B. A., Lonidamine: in vitro/in vivo correlations. Eur. J. Cancer, 30A: 1411-1413, 1994.
31. Farber, E. ATP and cell integrity. Fed. Proc., 32: 1534-1539, 1973.
32. Bates, S. E., Currier, S. S., Alvares, M. A., and Fojo, A. T. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry, 31: 6366-6372, 1992.
33. Simon, S. M., Roy, D., and Schindler, M. Intracellular pH in the control of multidrug resistance. Proc. Natl. Acad. Sci. USA, 91: 1128-1132, 1994.
34. 13C nuclear magnetic resonance studies. Cancer Res., 55: 2814-21, 1995.
35. Vivi. A., Tassini, M., Ben-Horin, H., Navon, G., and Kaplan, O. Comparison of action of antineoplastic drug lonidamine between drug-sensitive and drug-resistant MCF-7 human breast cancer cells. In: Proceedings of the Third International Conference of the Magnetic Resonance Society, pp. 1699-1699 Nice, France: 1995.
36. 13C nuclear magnetic resonance studies. Breast Cancer Res. Treat., 43: 15-25, 1997.
37. Floridi, A., Bruno, T., Miccadei, S., Fanciulli, M., Federico, A., and Paggi, M. G. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem. Pharmacol., 56; 841-849, 1998.
38. Oudard, S., Poirson, F., Miccoli, L., Bourgeois, Y., Vassault, A., Poisson, M., Magdelenat, H., Dutrillaux, B., and Poupon, M. F., Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int. J. Cancer, 62: 216-222, 1995.
39. Dell'Antone, P., and Piergallini, L. The antineoplastic drug lonidamine interferes with the acidification mechanism of cell organelles. Biochim. Biophys. Acta, 1358: 46-52, 1997.
40. Citro, G., Cucco, C., Verdina, A., and Zupi, G. Reversal of adriamycin resistance by ionidamine in human breast cancer cell line. Br. J. Cancer, 64: 534-536, 1991.
41. Teicher, B. A., Holden, S. A., Herman, T. S., and Frei, E., III. Modulation of alkylating agents by lonidamine in vivo. Semin. Oncol., 18 (Suppl. 2): 7-10, 1991.
42. Rosbe, K. W. Brann, T. W., Holden, S. A., Teicher, B. A., and Frei, E., III. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother. Pharmacol., 25: 32-36, 1989.
43. Kim, J. H., Alfieri, A. A., Kim, S. H., and Young, C. W. Potentiation of radiation effects of two murine tumors by lonidamine. Cancer Res., 46: 1220-1223, 1986.
44. Raaphorst, G. P., Feeley, M. M., Danjoux, C. E., Matrin, L., Mariun, J., and De Santis, J. The effect of lonidamine (LND) on radiation and thermal response of human and rodent cell lines. Int. J. Radiat. Oncol. Biol. Phys., 20: 509-515, 1991.
45. Zupi, G., Greco, C., Laudonio, N., Benassi, M., Silvestrini, B., and Caputo, A., In vitro and in vivo potentiation of the antitumor effect of adriamycin. Anticancer Res., 6: 1245-1250, 1986.